Low-dose methotrexate in sickle-cell disease: a pilot study with rationale borrowed from rheumatoid arthritis
ConclusionsAlthough MTX did not reduce acute VOC frequency/intensity, it decreased chronic pain and led to QOL improvement.Trial registrationhttp://www.who.int/ictrp/en/ andhttp://www.ensaiosclinicos.gov.br, RBR-2s9xvn, 19 December 2016, retrospectively registered
Source: Experimental Hematology and Oncology - Category: Cancer & Oncology Source Type: research
More News: Arthritis | Cancer & Oncology | Chronic Pain | Dengue Fever | Hematology | Methotrexate | Pain | Pneumonia | Respiratory Medicine | Rheumatoid Arthritis | Rheumatology | Septic Shock | Sickle Cell Anemia | Study | Toxicology